Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2021)

Lineage Cell Therapeutics (LCTX) has 4 years of Non Operating Investment Income data on record, last reported at $6.0 million in Q1 2021.

  • For Q1 2021, Non Operating Investment Income rose 378.86% year-over-year to $6.0 million; the TTM value through Sep 2021 reached $6.7 million, up 709.59%, while the annual FY2021 figure was $6.0 million, 32.11% up from the prior year.
  • Non Operating Investment Income reached $6.0 million in Q1 2021 per LCTX's latest filing, up from $712000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $6.0 million in Q1 2021 and bottomed at -$5.0 million in Q4 2019.
  • Average Non Operating Investment Income over 4 years is $782153.8, with a median of $523000.0 recorded in 2018.
  • The widest YoY moves for Non Operating Investment Income: up 8834.78% in 2019, down 1047.04% in 2019.
  • A 4-year view of Non Operating Investment Income shows it stood at $523000.0 in 2018, then plummeted by 1047.04% to -$5.0 million in 2019, then surged by 114.38% to $712000.0 in 2020, then skyrocketed by 746.07% to $6.0 million in 2021.
  • Per Business Quant database, its latest 3 readings for Non Operating Investment Income were $6.0 million in Q1 2021, $712000.0 in Q4 2020, and $120000.0 in Q3 2020.